Exhibit 10.25
AMENDMENT NO. 1 TO
MANUFACTURE AND SUPPLY AGREEMENT
This Amendment No. 1 is made to the Manufacture and Supply Agreement made
December 9, 2003, ("the Agreement") by and between Luitpold Pharmaceuticals,
Inc., a New York corporation ("Luitpold") and BioMimetic Therapeutics, Inc.
(formerly BioMimetic Pharmaceuticals, Inc.), a Delaware corporation ("BMTI")
(each, individually a "Party" and collectively, the "Parties") as of this 21th
day of December, 2005.
WHEREAS, the Term of the Agreement was to extend until the seventh
anniversary date of the Effective Date of the Agreement; and
WHEREAS, the Parties have agreed to extend the Term of the Agreement;
NOW, THEREFORE, in consideration of the mutual premises, covenants, and
agreements hereinafter set forth, the sufficiency of which is hereby
acknowledged, the Parties to the Agreement, intending to be bound, mutually
agree as follows:
1. Section 11.1 of the Agreement is amended as follows:
"The term of this Agreement shall be for a period beginning on the
Effective Date and shall continue until December 31, 2026 (the
"Initial Term"). This Agreement shall renew at the end of the
Initial Term for subsequent five (5) year renewal terms (each, a
"Renewal Term," and together with the Initial Term, the "Term"),
unless either party gives at least six (6) months notice of intent
not to renew."
2. Except as otherwise expressly amended above, all provisions of the
Agreement shall continue to remain in full force and effect.
IN WITNESS WHEREOF, Luitpold and BMTI have entered into this Amendment No.
1 effective as of the date hereinabove written, each by a duly authorized
officer, in duplicate originals.
LUITPOLD PHARMACEUTICALS, INC. BIOMIMETIC THERAPEUTICS, INC.
By:/s/ Xxxx Xxxx Xxxxxxx By:/s/ Xxxxxx Xxxxx
------------------------------------------- ------------------------
Xxxx Xxxx Xxxxxxx, R. Ph., M.S., M.B.A. Xxxxxx Xxxxx, D.D.S.
Preisedent and CEO President and CEO
- 2 -
